Navigation Links
Chem Rx Corporation Reports Full Year 2007 Financial Results
Date:4/3/2008

be a hallmark of our business and a key factor to our client retention and bed growth. We successfully executed our expansion strategy through acquisitions and by opening new facilities. At the end of October, we completed the business combination and are now a public operating entity with an expanding institutional pharmacy business."

Steven C. Silva, President and Chief Operating Officer, stated, "Our 2007 operating results for the combined entity on a pro forma basis were reflective of the challenges that we faced during this transition period. The South Plainfield, New Jersey location that opened in August 2006 generated positive operating results, but lower than anticipated operating margins. We continue to successfully add beds in New Jersey and are taking steps to enhance systems aimed at margin improvement. Our institutional pharmacy center in Pennsylvania, which we acquired in January 2007, posted a small operating loss as we transitioned operations to our platform in advance of bringing on new customers. In line with the industry, our business incurred higher delivery expenses, an increase in the reserve for doubtful accounts, and was exposed to increased competition from smaller local players."

Mr. Silva continued, "Since completing our business combination at the end of October 2007, we have increased total beds by 4.4% through the end of February with over 65,000 residents served. We continue to improve our IT infrastructure with investments in new systems and software, which enables us to operate more efficiently and provide better service to our customers. We commenced operations at our fifth institutional pharmacy facility located in Deerfield Beach, Florida on April 1, 2008 and look forward to adding beds in the South Florida market. We anticipate improvement throughout the year with better results in the second half of the year as we benefit from continued net bed growth and implement certain expense reduction initiatives."

Pr
'/>"/>

SOURCE Chem Rx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... are continually reaching new lows as they reduce the temperatures ... low enough to overcome the entropy (a measure of the ... discovery of exotic states of ultra-cold matter. Now physicists at ... out of a collection of atoms in much the same ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... Hardev Pandha of the Royal Surrey County Hospital, U.K., ... of Clinical Cancer Research. The paper is entitled "Synergistic ... Malignant Melanoma." , The research demonstrated that the innate ...
... , CAMBRIDGE, Mass., Sept. 24 Peptimmune, Inc. ... has formed a research and development collaboration with the Walter ... Research Center (NMRC), Silver Spring, MD to evaluate the Company,s ... dengue vaccines and point-of-care diagnostics. , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial 2Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities 2
(Date:8/19/2014)... UK 19 August 2014: An engineer at the ... despite not having a brain to communicate with the ... Harvard, Professor L Mahadevan, has developed a mathematical model ... view of how these soft bodied animals get around. ... the central pattern generator (CPG) which states that the ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
(Date:8/19/2014)... exist in different forms, they have not been widely ... Now researchers from the University of Surrey and Trinity ... elastic bands with graphene, to create a flexible sensor ... be made cheaply. , Once treated, the rubber ... graphene - which imparts an electromechanical response on movement ...
Breaking Biology News(10 mins):Secrets of how worms wriggle uncovered 2
... by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, ... Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer ... label Human Immunodeficiency Viruses (HIV) for visual investigations ... , The labeling permits scientists to observe the ...
... bugs, according to Gilbert Waldbauer, whose book "Insights From Insects: ... (Prometheus Books). , "We know a lot about pests, because ... professor emeritus of entomology at the University of Illinois at ... 2 percent are considered pests. Just as some plants growing ...
... synthesis of QS-21A, a medicinally important molecule that helps ... at the University of Illinois at Urbana-Champaign. , In ... the body's immune response in vaccine therapies against aggressive ... prostate cancer, HIV-1 and malaria. An extract from the ...
Cached Biology News:Virologists make major step towards understanding the process of HIV infection 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 3
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
... Clone/PAD: ZMD.440. Immunogen: Synthetic peptide derived ... PDGF-D (platelet derived growth factor D iris-expressed ... which differs from mouse and rat by ... with the ~50 kDa human mouse and ...
Biology Products: